Title:Targeting Host Store-Operated Ca<sup>2+</sup> Release to Attenuate Viral Infections
VOLUME: 13 ISSUE: 16
Author(s):Kevin B. Clark and E. M. Eisenstein
Affiliation:4229 S.E. Harney Street, Portland, OR, 97206-0941, USA.
Keywords:diarrhea, intracellular Ca2+ signaling, IP3 pathway and receptors, protein-protein allostery, T cells, viral replication,
virus-associated dementia, virus-induced cytotoxicity.
Abstract:Viruses coopt host intracellular Ca2+ signaling pathways to optimize timing and effectiveness of infection
stages against barriers to invasion, pathogenesis, replication, and release. Virus-induced changes in free cytosolic Ca2+
levels facilitate virus adsorption, uncoating, catalysis, toxin production, structural assembly and stabilization, trafficking,
and fusion and budding. Ca2+-associated alterations in virus status also selectively precipitate host cytopathologies
through, among other events, retardation or induction of apoptosis, elevation of metabolic stress and reactive oxygen species
production, and promotion of proinflammatory cytokine and chemokine synthesis and release. Viral particles and proteins
tune spatiotemporal dynamics of host free cytosolic Ca2+ concentrations by modulating Ca2+ entry from the extracellular
environment, upstream first or second messengers, ion- and ATP-dependent Ca2+ pumps that sequester or extrude
free cytosolic Ca2+, store-operated Ca2+ mobilization and leakage, and viral capsid/envelope and downstream host Ca2+
binding proteins and sensors. Each of these major viral mechanisms, briefly reviewed in this article, presents a suitable
drug target capable of mitigating the severity and incidence of viral infections. Given its pivotal role in cellular response
regulation, bioenergetics, posttranslational protein and lipid modification and transport, homeostasis, cell motility and
morphogenesis, and T lymphocyte proliferation, targeting virally stimulated inositol 1,4,5-trisphoshate (IP3)-mediated
store-operated Ca2+ release especially offers unique, predictable benefits for augmenting immunoprotection in vertebrate
clinical populations. We appraise possibilities of modulating this system with experimental proteins that gate activation
kinetics of endoplasmic-reticulum-localized Ca2+-conducting IP3 receptors via allosteric protein-protein interactions. Such
compounds are expected to be valuable in treating primary disease symptoms and sequelae, including virus-associated
dementia.
